Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors

MeSH terms

• Anemia, Hypochromic / chemically induced
• Anemia, Hypochromic / drug therapy*
• Anemia, Hypochromic / etiology*
• Anemia, Hypochromic / prevention & control
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects*
• Breast Neoplasms / drug therapy
• Carcinoma, Small Cell / drug therapy
• Clinical Protocols
• Darbepoetin alfa
• Data Interpretation, Statistical
• Erythropoietin / administration & dosage
• Erythropoietin / agonists
• Erythropoietin / analogs & derivatives
• Female
• Filgrastim
• Follow-Up Studies
• Graft vs Host Disease / drug therapy
• Granulocyte Colony-Stimulating Factor / administration & dosage
• Granulocytes / drug effects
• Hematinics / therapeutic use*
• Hematologic Neoplasms / drug therapy
• Hematopoietic Cell Growth Factors / therapeutic use*
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunoglobulins, Intravenous / therapeutic use
• Lung Neoplasms / drug therapy
• Lymphoma / drug therapy
• Lymphoma, Non-Hodgkin / drug therapy
• Male
• Multicenter Studies as Topic
• Neoplasms / complications*
• Neoplasms / drug therapy*
• Neoplasms / mortality
• Neutropenia / drug therapy
• Neutropenia / etiology
• Platelet Aggregation Inhibitors / administration & dosage
• Polycythemia Vera / drug therapy
• Polyethylene Glycols
• Randomized Controlled Trials as Topic / methods
• Randomized Controlled Trials as Topic / standards
• Recombinant Proteins
• Research Design
• Survival Analysis
• Thrombocythemia, Essential / drug therapy
• Treatment Outcome